PreciseBreast™ has the potential to ship vital financial savings to payers and sufferers, whereas offering a extra correct measure of medical threat; in the end supporting remedy and administration selections for all sufferers with invasive breast most cancers
NEW YORK, July 23, 2024 /PRNewswire/ — PreciseDx®, a number one innovator in oncology diagnostics leveraging Synthetic Intelligence (AI) for revolutionary, morphology-driven illness evaluation, at the moment introduced that its financial influence examine for PreciseBreast™ threat evaluation has been revealed within the July problem of the Journal of Medical Economics.
The examine calculated the associated fee influence of utilizing PreciseBreast™(additionally known as PDxBr), an AI histopathology platform that predicts the 6-year threat of recurrence in early-stage invasive breast most cancers (IBC) sufferers to assist within the remedy resolution course of (i.e. use of chemotherapy). The examine in contrast the prices of remedy guided by customary of care (SOC) threat evaluation (i.e., 21 gene expression check and histopathology evaluation) versus PreciseBreast™ along side SOC. A hypothetical cohort of 1 million U.S. ladies with early-stage invasive breast most cancers was used for the examine.
Value influence thought of the price of testing, adjuvant remedy, recurrence, opposed occasions, surveillance, and end-of-life care from a industrial payer perspective. The findings are compelling: when used as a part of a recurrence threat analysis in a hypothetical cohort of 1 million feminine members, use of PreciseBreast™ resulted in value financial savings of $4M in yr one in comparison with the present customary of care alone. Over 6 years, the financial savings elevated to $12.5M. The per-treated affected person prices calculated in yr one have been $19.5K for conventional customary of care and $16.9K for PreciseBreast™.
“We’re very happy with these findings and the potential influence on each healthcare prices and affected person care,” mentioned Michael J. Donovan, Co-founder and Chief Medical Officer of PreciseDx. “With PreciseBreast, we’re probably shielding many low-risk sufferers from the pointless toxicity of chemotherapy, whereas additionally offering vital financial savings to payers. As well as, PreciseBreast is a digital prognostic check which depends on the affected person’s personal available diagnostic tissue specimen from the pathology lab, guaranteeing accessibility to oncologists and pathologists no matter geographic location.”
PreciseBreast™ makes use of Synthetic Intelligence (AI) and Machine Studying (ML) mixed with its Morphology Characteristic Array (MFA®) to investigate invasive breast most cancers histology photographs with the aim of enhancing and bettering the normal grading strategy. PreciseBreast™ is an in vitro prognostic check that predicts breast most cancers recurrence for sufferers identified with early-stage IBC.
“Our validated AI-powered MFA platform (utilizing digital entire slide picture evaluation) is altering how we will assess and analyze affected person knowledge to positively influence healthcare,” mentioned Ted Diehl, Vice President of Industrial Growth at PreciseDx. “For breast most cancers sufferers and their physicians, PreciseBreast is offering correct and goal threat stratification inside 48 hours at 20% the price of gene expression testing. PreciseBreast supplies an correct and efficient sequence to gene expression testing and was established to boost present histopathology evaluation that’s accessible, inexpensive, and simply obtainable.”
About PreciseDx®
PreciseDx® is innovating oncology diagnostics, leveraging Synthetic Intelligence (AI) for revolutionary, morphology-driven illness evaluation. Combining AI with our patented Morphology Characteristic Array® (MFA), PreciseDx supplies entry to unmatched illness insights and correct, actionable intelligence for extra complete decision-making all through the most cancers care continuum. To be taught extra about PreciseDx, go to https://precisedx.ai/
About PreciseBreast™
PreciseBreast™ is an early-stage invasive breast most cancers threat evaluation, impartial of HER2, and hormone receptor standing. The AI-powered check makes use of customary H&E pathology slide photographs. Leveraging hundreds of thousands of knowledge factors, PreciseBreast™ analyzes, correlates, and quantifies these vital options that predict breast most cancers recurrence and delivers a Threat of Recurrence Rating. The check meets the rigorous Scientific Laboratory Enchancment Amendments (CLIA) requirements and has handed the Scientific Laboratory Analysis Program (CLEP) Assay Validation Assessment by the New York State Division of Well being (NYSDOH). PDxBr shall be obtainable worldwide underneath the model identify of PreciseBreast™. For extra info, please contact [email protected].
For media inquiries or additional info, please contact:
Hannah Davis
860-707-9461
[email protected]
SOURCE PreciseDx
